Abstract: The present invention relates to antimalarial compounds and their use against protozoa of the genus Plasmodium, including drug-resistant Plasmodia strains. This invention further relates to compositions containing such compounds and a process for making the compounds.

Abstract: The present invention relates to antimalarial compounds and their use against protozoa of the genus Plasmodium, including drug-resistant Plasmodia strains. This invention further relates to compositions containing such compounds and a process for making the compounds.

Abstract: The present invention relates to antimalarial compounds and their use against protozoa of the genus Plasmodium, including drug-resistant Plasmodia strains. This invention further relates to compositions containing such compounds and a process for making the compounds.

Abstract: The present invention relates to antimalarial compounds and their use against protozoa of the genus Plasmodium, including drug-resistant Plasmodia strains. This invention further relates to compositions containing such compounds and a process for making the compounds.

Abstract: The present invention relates to antimalarial compounds and their use against protozoa of the genus Plasmodium, including drug-resistant Plasmodia strains. This invention further relates to compositions containing such compounds and a process for making the compounds.

Abstract: The present invention relates to antimalarial compounds and their use against protozoa of the genus Plasmodium, including drug-resistant Plasmodia strains. This invention further relates to compositions containing such compounds and a process for making the compounds.

Abstract: Biguanide and dihydrotriazine derivatives, preferably substituted asymmetrical imidodicarbonimidic diamides derived from hydroxylamines, and compositions containing biguanide and dihydrotriazine derivatives are disclosed. In addition, methods of using the biguanide and dihydrotriazine derivatives, inter alia, as antimicrobial agents and methods of using the dihydrotriazine derivatives in biological assays are disclosed. Methods of making the biguanide and dihydrotriazine derivatives are also disclosed.

Abstract: The present invention relates to the use of compounds of formula (I), wherein R is C1-C8-alkyl, unsubstituted or substituted with 1, 2 or 3 radicals selected from the group consisting of halogen, amino, nitro, cyano, C1-C4-alkenyl, C1-C4-haloalkenyl, C1-C4-alkoxy, C1-C4-haloalkoxy, C1-C4-alkylthio, 5- to 10-membered heteroaryl containing as ring members 1, 2, 3 or 4 heteroatoms selected from oxygen, sulfur and nitrogen, and phenyl, wherein the heteroaryl and phenyl radicals may be substituted for the control of nematodes, a method for the control of nematodes, and a method for the protection of plants from infestation or attack by nematodes.

Abstract: Biguanide and dihydrotriazine derivatives, preferably substituted asymmetrical imidodicarbonimidic diamides derived from hydroxylamines, and compositions containing biguanide and dihydrotriazine derivatives are disclosed. In addition, methods of using the biguanide and dihydrotriazine derivatives, inter alia, as antimicrobial agents and methods of using the dihydrotriazine derivatives in biological assays are disclosed. Methods of making the biguanide and dihydrotriazine derivatives are also disclosed.

Abstract: The present invention relates to new azine compounds which are useful combating animal pests, in particular insects and nematodes and to the salts thereof. The invention also relates to a method for combating insects, nematodes and arachnids. The azine compounds of the invention are described by the general formula (I) wherein . . . is absent or a covalent bond; n is 0 or 1, in particular 0; A is an optionally substituted cyclic radical selected from phenyl and a 5- or 6-membered heterocyclic radical with 1, 2, 3, or 4 heteroatoms; Ar is an optionally substituted aromatic radical selected from phenyl, pyridyl, pyrimidyl, furyl and thienyl, x is selected from halogen, OR7, SR7, SOR7, SO2R7, C1-C4-alkyl and C1-C4-haloalkyl; and wherein R1 to R4 and R7 are as described in the claims and the specification.

Abstract: Biguanide and dihydrotriazine derivatives, preferably substituted asymmetrical imidodicarbonimidic diamides derived from hydroxylamines, and compositions containing biguanide and dihydrotriazine derivatives are disclosed. In addition, methods of using the biguanide and dihydrotriazine derivatives, inter alia, as antimicrobial agents and methods of using the dihydrotriazine derivatives in biological assays are disclosed. Methods of making the biguanide and dihydrotriazine derivatives are also disclosed.

Abstract: The present invention relates to a method for combating insects or arachnids which comprises contacting the insects or the arachnids, their habitat, breeding ground, food supply, plant, seed, soil, area, material or environment in which the insects or the arachnids are growing or may grow, or the materials, plants, seeds, soils, surfaces or spaces to be protected from insect or arachnid attack or infestation with a pesticidally effective amount of a compound of the general formula (I) or a salt thereof wherein: Ar is a cyclic radical, n is 0 or 1, X is CO or SO2 and R1 to R4 are as defined in claim 1.

Abstract: The present invention relates to the use of compounds of formula (I), wherein R is C1-C8-alkyl, unsubstituted or substituted with 1, 2 or 3 radicals selected from the group consisting of halogen, amino, nitro, cyano, C1-C4-alkenyl, C1-C4-haloalkenyl, C1-C4-alkoxy, C1-C4-haloalkoxy, C1-C4-alkylthio, 5- to 10-membered heteroaryl containing as ring members 1, 2, 3 or 4 heteroatoms selected from oxygen, sulfur and nitrogen, and phenyl, wherein the heteroaryl and phenyl radicals may be substituted for the control of nematodes, a method for the control of nematodes, and a method for the protection of plants from infestation or attack by nematodes.

Abstract: Biguanide and dihydrotriazine derivatives, preferably substituted asymmetrical imidodicarbonimidic diamides derived from hydroxylamines, and compositions containing biguanide and dihydrotriazine derivatives are disclosed. In addition, methods of using the biguanide and dihydrotriazine derivatives, inter alia, as antimicrobial agents and methods of using the dihydrotriazine derivatives in biological assays are disclosed. Methods of making the biguanide and dihydrotriazine derivatives are also disclosed.

Abstract: The present invention relates to physiologically-active derivatized natural and recombinant mammalian and human proteins and polypeptides. The invention provides chemical methods for derivatizing natural and recombinantly-derived proteins or polypeptides containing cysteine residues, either naturally or through site specific mutageneses. The pharmaceutical compositions containing said derivatized proteins and/or polypeptides are formulated to provide stable, long-acting compositions of such proteins and/or polypeptides, previously difficult to achieve.

Abstract: The present invention relates to physiologically-active derivatized natural and recombinant mammalian and human proteins and polypeptides. The invention provides chemical methods for derivatizing natural and recombinantly-derived proteins or polypeptides containing cysteine residues, either naturally or through site specific mutageneses. The pharmaceutical compositions containing the derivatized proteins and/or polypeptides are formulated to provide stable, long-acting compositions of such proteins and/or polypeptides, previously difficult to achieve.

Abstract: An isolated polypeptide corresponding to the epitope of porcine somatotropin is provided by this invention as well as methods of enhancing the growth of an animal by administering to the animal this polypeptide in compositions.

Abstract: An isolated polypeptide corresponding to the epitope of porcine somatotropin is provided by this invention as well as methods of enhancing the growth of an animal by administering to the animal this polypeptide in compositions.

Abstract: The invention relates to a purified somatostatin receptor which is purified at least about 30,000-fold over the receptor which is membrane-bound. The invention also provides pharmaceutical compositions containing the receptor and antibodies to the receptor.

Abstract: The receptor:ligand complex is applied to a solid phase substrate which binds the complex by specifically binding the ligand. The receptor is dissociated from the substrate bound receptor:ligand complex with an eluant capable of releasing the receptor from the ligand and leaving the ligand bound to the solid phase substrate. GTP containing eluants are effective. The receptor is recovered from the eluate and optionally subjected to further purification.